9,302 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Acquired by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG purchased a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 9,302 shares of the specialty pharmaceutical company's stock, valued at approximately $1,146,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. OneDigital Investment Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 35.2% during the 4th quarter. OneDigital Investment Advisors LLC now owns 3,555 shares of the specialty pharmaceutical company's stock worth $438,000 after buying an additional 926 shares during the period. Stifel Financial Corp boosted its holdings in shares of Jazz Pharmaceuticals by 25.5% during the fourth quarter. Stifel Financial Corp now owns 178,328 shares of the specialty pharmaceutical company's stock worth $21,961,000 after acquiring an additional 36,253 shares during the period. State of Tennessee Department of Treasury grew its position in shares of Jazz Pharmaceuticals by 5.8% in the fourth quarter. State of Tennessee Department of Treasury now owns 28,654 shares of the specialty pharmaceutical company's stock valued at $3,529,000 after purchasing an additional 1,568 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Jazz Pharmaceuticals by 238.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,025 shares of the specialty pharmaceutical company's stock worth $373,000 after purchasing an additional 2,132 shares during the period. Finally, MML Investors Services LLC acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $1,785,000. 89.14% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on JAZZ shares. Cantor Fitzgerald cut Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and increased their price objective for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. HC Wainwright raised their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Piper Sandler reissued an "overweight" rating and issued a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. Morgan Stanley reaffirmed an "overweight" rating and set a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. Finally, UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price target for the company from $145.00 to $179.00 in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $187.71.

Insider Activity at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 4,813 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the transaction, the chief accounting officer now owns 8,237 shares of the company's stock, valued at $1,189,587.54. This represents a 36.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Robert Iannone sold 7,080 shares of the business's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the sale, the chief marketing officer now directly owns 82,024 shares in the company, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock valued at $4,023,305 over the last ninety days. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Trading Up 3.0 %

Shares of JAZZ opened at $103.38 on Wednesday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 52-week low of $95.49 and a 52-week high of $148.06. The firm has a market cap of $6.28 billion, a price-to-earnings ratio of 14.56, a PEG ratio of 1.04 and a beta of 0.42. The business's fifty day moving average is $126.23 and its 200-day moving average is $122.31.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.